Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.
Haanen JB, Baars A, Gomez R, Weder P, Smits M, de Gruijl TD, von Blomberg BM, Bloemena E, Scheper RJ, van Ham SM, Pinedo HM, van den Eertwegh AJ. Haanen JB, et al. Among authors: van ham sm, van den eertwegh aj. Cancer Immunol Immunother. 2006 Apr;55(4):451-8. doi: 10.1007/s00262-005-0018-5. Epub 2005 Jul 21. Cancer Immunol Immunother. 2006. PMID: 16034562 Free PMC article. Clinical Trial.
An ex vivo readout for evaluation of dendritic cell-induced autologous cytotoxic T lymphocyte responses against esophageal cancer.
Milano F, Rygiel AM, Buttar N, Bergman JJ, Sondermeijer C, van Baal JW, ten Brinke A, Kapsenberg M, van Ham SM, Peppelenbosch MP, Krishnadath KK. Milano F, et al. Among authors: van ham sm, van baal jw. Cancer Immunol Immunother. 2007 Dec;56(12):1967-77. doi: 10.1007/s00262-007-0341-0. Epub 2007 Jun 13. Cancer Immunol Immunother. 2007. PMID: 17564704 Free PMC article.
Monophosphoryl lipid A plus IFNgamma maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential.
ten Brinke A, van Schijndel G, Visser R, de Gruijl TD, Zwaginga JJ, van Ham SM. ten Brinke A, et al. Among authors: van ham sm, van schijndel g. Cancer Immunol Immunother. 2010 Aug;59(8):1185-95. doi: 10.1007/s00262-010-0843-z. Epub 2010 Mar 25. Cancer Immunol Immunother. 2010. PMID: 20336295 Free PMC article.
Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.
van Luijn MM, Chamuleau ME, Ressing ME, Wiertz EJ, Ostrand-Rosenberg S, Souwer Y, Zevenbergen A, Ossenkoppele GJ, van de Loosdrecht AA, van Ham SM. van Luijn MM, et al. Among authors: van ham sm, van de loosdrecht aa. Cancer Immunol Immunother. 2010 Dec;59(12):1825-38. doi: 10.1007/s00262-010-0908-z. Epub 2010 Sep 5. Cancer Immunol Immunother. 2010. PMID: 20820776 Free PMC article.
Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.
van Luijn MM, van den Ancker W, Chamuleau ME, Zevenbergen A, Westers TM, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA. van Luijn MM, et al. Among authors: van den ancker w, van ham sm, van de loosdrecht aa. Cancer Res. 2011 Apr 1;71(7):2507-17. doi: 10.1158/0008-5472.CAN-10-3689. Epub 2011 Feb 10. Cancer Res. 2011. PMID: 21310823 Free article.
Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.
Koster BD, Santegoets SJAM, Harting J, Baars A, van Ham SM, Scheper RJ, Hooijberg E, de Gruijl TD, van den Eertwegh AJM. Koster BD, et al. Among authors: van ham sm, van den eertwegh ajm. Cancer Immunol Immunother. 2019 Jun;68(6):1025-1035. doi: 10.1007/s00262-019-02320-0. Epub 2019 Mar 9. Cancer Immunol Immunother. 2019. PMID: 30852622 Free PMC article. Clinical Trial.
Correction to: Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.
Koster BD, Santegoets SJAM, Harting J, Baars A, van Ham SM, Scheper RJ, Hooijberg E, de Gruijl TD, van den Eertwegh AJM. Koster BD, et al. Among authors: van ham sm, van den eertwegh ajm. Cancer Immunol Immunother. 2019 Jun;68(6):1037. doi: 10.1007/s00262-019-02328-6. Cancer Immunol Immunother. 2019. PMID: 30919028 Free PMC article.
Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.
van Luijn MM, Chamuleau ME, Thompson JA, Ostrand-Rosenberg S, Westers TM, Souwer Y, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA. van Luijn MM, et al. Among authors: van ham sm, van de loosdrecht aa. Haematologica. 2010 Mar;95(3):485-93. doi: 10.3324/haematol.2009.010595. Epub 2009 Nov 10. Haematologica. 2010. PMID: 19903675 Free PMC article.
120 results